Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2005
08/10/2005CN1213755C Use of exemestane in preparing medicinal composition for first-line treatment of breast cancer
08/10/2005CN1213746C Immunopotentiatory agents and physiologically acceptable salts thereof
08/10/2005CN1213744C Remedies
08/10/2005CN1213733C Method of preparing stable suspension of insoluble microparticles
08/09/2005US6927234 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
08/09/2005US6927231 and stress-related degenerative processes associated with aging or diseases such as cancer, neurodegenerative disease or dysregulation of redox-regulated physiological processes, indicated by prooxidative shift in plasma thiol/disulfide redox state
08/09/2005US6927230 Triazole derivatives
08/09/2005US6927228 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation
08/09/2005US6927224 Anticancer agents; osteoporosis
08/09/2005US6927222 Compounds
08/09/2005US6927220 Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
08/09/2005US6927219 Secondary amides such as N-Adamantan-1-methyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H- (1,2,4)triazin-2-yl)-benzamide used as antagonists for biological receptors; antiinflammatiory, anticarcinogenic or antiischemic agents
08/09/2005US6927218 Aryl N-cyanoguanidines and methods related thereto
08/09/2005US6927211 Method for reducing toxicity of combined chemotherapies
08/09/2005US6927061 Capable of differentiating into ovarian surface epithelial and granulosa cells
08/09/2005US6927054 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects
08/09/2005US6926898 Albumin fusion proteins
08/09/2005US6926893 Multi-stage cascade boosting vaccine
08/09/2005US6926888 producer cell ( encapsulated in a matrix which containing alginates) containing a plasmid that includes a nucleic acid sequence that encodes endostatin, angiostatin, thrombospondin, or prolactin
08/09/2005CA2095659C Heteroatoms-containing tricyclic compounds
08/04/2005WO2005071084A1 Construction of gutted recombinant adenovirus effectively expressing antibodies comprising human constant region and uses thereof
08/04/2005WO2005071082A1 Antisense oligonucleotide having anticancerous activity
08/04/2005WO2005070936A1 20-esterized camptothecin derivatives, their preparation and the pharmaceutical compositions and the use
08/04/2005WO2005070923A1 Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
08/04/2005WO2005070469A1 Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
08/04/2005WO2005070459A1 Method of continuing expression of vector repeatedly administered
08/04/2005WO2005070416A1 Indirubin derivatives having anticancer property against human cancer cell me
08/04/2005WO2005070415A1 Adjuvant compositions
08/04/2005WO2005069894A2 Conformationally constrained smac mimetics and the uses thereof
08/04/2005WO2005069771A2 Small molecule antagonists of bcl-2 family proteins
08/04/2005WO2005058245A3 Synthetic process
08/04/2005WO2004053487A8 METHOD OF DIAGNOSIS,TREATMENT AND USEFUL AGENTS FOR CONDITIONS CHARACTERISED BY MODULATION IN THE LEVEL OF ACTIVIN βC
08/04/2005WO2004031413A9 Method for diagnosing non-small cell lung cancers
08/04/2005WO2004007457A3 Substituted benzylamine derivatives and methods of use
08/04/2005US20050172352 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/04/2005US20050171353 Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
08/04/2005US20050171350 Benzhydryl derivatives
08/04/2005US20050171347 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
08/04/2005US20050171346 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections
08/04/2005US20050171186 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171162 Crystals of benzimidazole compounds
08/04/2005US20050171158 1-(sulfonylaminomethylcarbonyl)-4-cyclohexylpiperidine compounds such as N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide; various diseases and disorders such as weight control, eating disorders
08/04/2005US20050171157 Substituted piperidines
08/04/2005US20050171154 Carboxylic acid amides
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171137 derivatives of Hemiasterlin or Geodiamolide G; pyrido(3,4-B)indole amides; extraction from marine sponges; anti-mitotic and carcinogenic agent; cause mitotic arrest and produce abnormal mitotic spindles
08/04/2005US20050171134 such as 4-[4-(1-Amino-1-methylethyl)phenyl]-5-chloro-N-[4-(2-hydroxyethyl)phenyl]pyrimidine-2-amine used as tyrosine kinase inhibitors, for prophylaxis disease states associated with angiogenesis
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171128 Pyrrolo[2,3-d]pyrimidine compounds
08/04/2005US20050171122 Mitotic kinesin inhibitors
08/04/2005US20050171114 Antitumor agents; superior cytotoxic activity; bioavailability; 1,2-dihydroxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[b]-chromeno[6,5-g][1,8]naphthyridin-7-one; adenocarcinomas and carcinomas, sarcomas, gliomas and leukaemias; Derivatives of acronycine
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171105 Methods and compositions as protein kinase inhibitors
08/04/2005US20050171103 Benzamide derivatives useful as histone deacetylase inhibitors
08/04/2005US20050171102 Semicarbazide derivatives for combating thromboembolic diseases
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171094 Pyrrolopyrimidine derivatives
08/04/2005US20050171091 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
08/04/2005US20050171087 high affinity agonists; high specificity; side effect reduction; endometriosis; hormone dependent cancers, fertility control; dibenzo[b,f]pyrido[1,2-d][1,4] oxazepin, dibenzo[b,f]pyrido[1,2-d][1,4]thiazepim, dibenzo[b,f]pyrido[1,2-d][1,4]diazepin and dibenzo[c,f]pyrido[1,2-a]azepine derivatives
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171060 Anticancer agents and drug delivery agents with nucleotides
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050171036 antitumor and anticarcinogenic agent; topoisomerase I inhibitor; synergistic effect by targeting different types of enzymes; low toxicity
08/04/2005US20050171031 Method and composition for the treatment of cancer
08/04/2005US20050171026 Inhibiting SF2/ASF-dependent splicing of beta-globin pre-mRNA in vitro by suppression of Clk-mediated phosphorylation of SR proteins (serine/arginine-rich); a benzothiazole, TG003, is inhibitor of Clk/Sty(CDC2-like kinases); anticancer, antitumor; neurodegenerative diseases
08/04/2005US20050171024 Modulating angiogenesis
08/04/2005US20050171019 Administering an exendin modified with a polymer such as polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes
08/04/2005US20050170504 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
08/04/2005US20050170500 Methods for identifying risk of melanoma and treatments thereof
08/04/2005US20050170411 Genes and proteins involved in the biosynthesis of enediyne ring structures
08/04/2005US20050170384 Expression vector comprising nucleotide sequences coding protein with sequence similarities to chordin proteins for use as tool in identifying modulator for treatment and prevention of infection and metabolic disorders
08/04/2005US20050170355 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases
08/04/2005US20050170348 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050169930 PSCA: prostate stem cell antigen and uses thereof
08/04/2005US20050169922 drug screening for compounds that enhance or suppress killer T cell activity by contacting killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005US20050169890 Recombinant vector; overexpresses an adenovirus death protein (ADP), is replication-restricted to neoplastic cells expressing telomerase
08/04/2005US20050169881 O(chloracetyl-carbamoyl) fumagillol -470 conjugated to hydroxypropyl(meth)acrylamide-methacrylic acid copolymer results in a water soluble composition, lowers the neurotoxicity of TNP-470, avoids penetration of TNP-470 to the cerebrospinal fluid
08/04/2005DE10246434B4 Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel Carboxyalkoxy-substituted acyl-carboxyphenyl urea derivatives and their use as medicaments
08/04/2005CA2595573A1 Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
08/04/2005CA2553986A1 Adjuvant compositions
08/04/2005CA2553883A1 Anti-cancer antibodies with reduced complement fixation
08/04/2005CA2553874A1 Conformationally constrained smac mimetics and the uses thereof
08/04/2005CA2553854A1 Immunomodulatory alkaloids
08/04/2005CA2553690A1 Topical co-enzyme q10 formulations and methods of use
08/04/2005CA2553513A1 N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
08/04/2005CA2553221A1 Folate conjugates and complexes
08/03/2005EP1559780A1 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
08/03/2005EP1559726A2 Growth differentiation factor-10
08/03/2005EP1559725A1 Antigen recognizing antibody
08/03/2005EP1559715A1 N-[2-chloro-4-(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
08/03/2005EP1559709A1 Heterocycle-containing carboxylic acid derivative and drug containing the same
08/03/2005EP1559708A1 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE
08/03/2005EP1559707A1 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
1 ... 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 ... 2211